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We used human papillomavirus type 16 (HPV-16) particles composed of capsid proteins L1 and L2 (L1/L2 capsids) as an
antigen to produce mouse monoclonal antibodies (MAbs). Of 18 MAbs recognizing surface epitopes of L1/L2 capsids, 1 was
an anti-L1 MAb and 17 were anti-L2 MAbs. Seven of 11 anti-L2 MAbs recognizing linear epitopes were found to bind to a
synthetic peptide with an HPV-16 L2 sequence of amino acids (aa) 69–81, which is within a highly conserved region among
different HPVs. The synthetic peptide reacted with the human sera that had been shown to be positive for an antibody against
HPV-16, -18, -58, or -6b capsids composed of L1 alone. The data suggest that the HPV-16 L2 region of aa 69–81 contains a
type-common immunodeterminant exposed on the surface of HPV virions. © 1998 Academic Press
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INTRODUCTION
Human papillomaviruses (HPVs), agents causing a
variety of epithelial lesions of the skin and genital tract,
are classified into more than 70 types, based on the
nucleotide sequence homology of viral DNA (Schiffman
et al., 1993). Despite overall similarity in the genomic
organization, HPVs have rather diverse tissue specificity
and malignant potential. Among the HPVs associated
with the lesions in an anogenital tract, HPV type 16
(HPV-16) is predominantly found in cervical cancers and
high-grade intraepithelial neoplasias (Lorincz et al., 1991;
Fisher, 1994).
An HPV capsid (an icosahedral particle with a diame-
ter of 55 nm) consists of 72 pentameric capsomeres
composed of the major (L1) and minor (L2) structural
proteins (Crawford and Crawford, 1963; Baker et al.,
1991). The molar ratio of capsid proteins L1 and L2 is
estimated to be 30 to 1 (Hagensee et al., 1993; Kirnbauer
et al., 1993). Characterization of surface epitopes of
these proteins is important to define neutralization
epitopes as well as to analyze topographical location in
the viral capsid. The surface epitopes on HPV-16 virus-
like particles composed of L1 alone (L1 capsids) have
been defined using mouse monoclonal antibodies
(MAbs) (Christensen et al., 1996) and antisera from pa-
tients with HPV infections (Wang et al., 1997). These
studies have shown that both linear and conformational
epitopes are on the surface of L1 capsids and that at
least three L1 regions [amino acids (aa) 111 to 130, 174 to
185, and 261 to 280] contain linear epitopes. On the other
hand, HPV-16 L2 regions of aa 32–51, 62–81, 212–231,
279–291, and 362–381 have been located on the surface
of L1/L2 capsids, from the observation that antisera
against the peptides containing aa sequences of the
regions react with HPV-16 L1/L2 capsids (Heino et al.,
1995). Studies of the other papillomaviruses identified a
conformational L2 epitope of HPV-33 (Volpers et al., 1995)
and linear L2 epitopes of HPV-1 (Yaegashi et al., 1991)
and BPV-1 (Wen et al., 1997).
In this study we examined epitopes that could be
recognized by a series of newly produced mouse anti-L2
MAbs reactive with HPV-16 particles produced in insect
Sf9 cells and composed of L1 and L2 (L1/L2 capsids). A
strong surface immunodeterminant was located in the L2
sequence of aa 69 to 81, which is in a highly conserved
region among different HPVs.
RESULTS
HPV-16 L1/L2 capsids
Composition of the HPV-16 L1/L2 capsids produced in
insect cells was verified by cosedimantation of L1 and L2
in centrifugation through a sucrose gradient. The purified
capsids (20 mg) were layered on the top of 5 ml of a 10
to 60% sucrose gradient in PBS and centrifuged in an
SW50.1 rotor (BECKMAN) at 40,000 rpm for 45 min at 4°C.
An aliquot (50 ml) of each fraction (0.3 ml from the bottom
of the tube) was incubated in a carbonate buffer (pH 9.6)
for 16 h at 4°C to disrupt capsids before measurement of
L1 and L2 by ELISA using a mouse monoclonal antibody
1 To whom reprint requests should be addressed. Fax: [181]-3-5285-
1166. E-mail: kanda@nih.go.jp.
VIROLOGY 245, 353–359 (1998)
ARTICLE NO. VY989168
0042-6822/98 $25.00
Copyright © 1998 by Academic Press
All rights of reproduction in any form reserved.
353
against HPV-16 L1 and the anti-L2 mouse antiserum (Fig.
1). Both L1 and L2 were detected in the same fractions
(fractions from 8 to 12). Spherical particles with a diam-
eter of 50–60 nm were observed exclusively in the pool
of the rest of these fractions by electron microscopy (Fig.
2A). The proteins in these fractions were electropho-
resed in SDS–polyacrylamide gels followed by silver
staining (Fig. 2B) and analyzed by Western blotting (Fig.
2C). The proteins with expected sizes (56 kDa for L1 and
;90 kDa for L2) (Kirnbauer et al., 1993) were detected.
The molar ratio of L1 to L2, although it could not be
calculated from electrophoresis, appeared to be reason-
able, as expected of HPV virions. These data indicate
that the purified particles were composed of L1 and L2.
Characterization of MAbs against the HPV-16 L1/L2
capsids
Eighteen stable hybridoma cell lines secreting
MAbs reactive with intact HPV-16 L1/L2 capsids were
obtained from mice immunized with L1/L2 capsids
(Table 1). Since further purification of antigen (L1/L2
capsids) for ELISA by sedimentation in a sucrose
gradient did not alter the reactivity of MAbs (data not
shown), we concluded that the MAbs did not react with
minor contaminants of disrupted capsids. Although the
sera from the immunized mice reacted with L1 capsids
(virus-like particles composed of only HPV-16 L1 pro-
tein) strongly, only one MAb (No. 32) was anti-L1. The
other 17 MAbs which did not react with L1 capsids
were anti-L2 antibodies recognizing epitopes dis-
played on the surface of L1/L2 capsids.
Reactivities of the anti-L2 MAbs with His-L2/330 (His-
tagged truncated L2 protein containing aa 1 to 330,
expressed in Sf9 cells), His-L2/173 (aa 1 to 173), bacte-
rially expressed MBP-L2 (the C-terminal 155-amino-acid
region fused with maltose binding protein), and GST-L2
[internal region (aa 141–243) fused with GST protein]
were examined by ELISA (Table 1 and Fig. 3). Eleven
MAbs (Nos. 17, 2, 4, 5, 6, 7, 9, 10, 11, 12, and 13) bound to
both His-L2/330 and His-L2/173. None of MAbs bound to
MBP-L2 and GST-L2. Therefore, it was indicated that
these MAbs recognized linear epitopes in the N-terminal
region of 140 amino acids. Six MAbs (Nos. 15, 16, 18, 24,
35, and 36) were not reactive with any of the four anti-
gens, indicating that their recognition epitopes are prob-
ably conformational.
The N-terminal unique regions (A: aa 1–12 and B: aa
56–81 of HPV-16 L2) in which amino acids sequences
are highly conserved among L2 of different HPVs (Fig.
4) attracted our attention. As to the immunological
cross-reactions, it is important to know whether the
conserved region contains the immunodeterminants.
Thus, 11 MAbs that recognized linear epitopes were
examined for reactivity with synthetic peptides with
amino acid sequences corresponding to those of the
conserved regions (Table 2). None of the MAbs re-
acted with P-1/12 and P-56/68. However, 6 MAbs (Nos.
2, 4, 6, 7, 9, and 10) bound to P-69/81. Since P-69/81
inhibited binding of these MAbs to L1/L2 capsids in
ELISA competitively (data not shown), we concluded
that the reactivities of the MAbs with P-69/81 were
specific. MAb 17 reacted with both P-63/75 and P-69/
81. The data indicated that the epitopes recognized by
the six MAbs contained, at least partly, the region of aa
69–81 and that the epitope for 17 contained the region
of aa 69–75. Epitopes for the other MAbs (Nos. 5, 11,
12, and 13) may be located in the region of aa 13–55 or
82–140.
Reactivity of human sera with P-69/81
To know the immunogenicity of the region of aa
69–81 to humans, reactivities of human sera to P-1/12,
P-56/68, and P-69/81 were examined by ELISA using
the serum samples selected from those previously
FIG. 1. Sucrose gradient sedimentation of HPV-16 L1/L2 capsids.
L1/L2 capsids purified by CsCl equilibrium density gradient centrifuga-
tion were sedimented in a sucrose gradient [10–60% (wt/vol) in PBS] by
centrifugation and fractionated (0.3 ml/fraction) from the bottom. L1 and
L2 proteins in each fraction were denatured in carbonate buffer (pH 9.6)
and measured by ELISA using anti-L1 and anti-L2 antibodies. Fractions
8 to 12 (indicated by a bold bar) were pooled and used for further
characterization.
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examined for antibodies against L1 capsids of HPV-6b,
-16, -18, and -58 (Matsumoto et al., 1997). The serum
samples analyzed were 20 samples negative for anti-
for HPV-6b, -16, -18, and -58, 22 samples positive for
the anti-HPV-16 L1 capsid antibody and negative for
the anti-HPV-6b, -18, and -58 L1 capsid antibodies, and
30 samples negative for anti-HPV-16 and positive for
any of anti-HPV-6b, -18, and -58. Figure 5 shows the
results obtained with the samples diluted in PBS (1:
50). Whereas the ELISA titers to P-1/12 and P-56/68
were low in all of the samples, those to P-69/81 were
high in the sera positive for any one of the anti-HPV L1
antibodies. Means of the titers of sera positive for
anti-HPV-16 and sera positive for any of anti-HPV-6b,
-18, and -58 were significantly higher than that of sera
negative for these antibodies. The data suggest that
the HPV-16 L2 region of aa 69–81 contains one of
immunodeterminants for humans as well as mice and
suggest that antisera against virions of different HPVs
contain antibodies cross-reactive to P-69/81.
TABLE 1
Characterization of 18 MAbs Reactive with L1/L2 Capsids
MAb
No. Subtype
ELISA titer (A450)
L1/L2 capsids L1 capsids His-L2/330 His-L2/173
17 IgM 0.242 0.000 0.133 0.102
2 IgM 0.156 0.000 0.154 0.113
4 IgG2a 0.115 0.000 0.141 0.101
6 IgG2a 0.161 0.000 0.128 0.102
7 IgM 0.181 0.055 0.111 0.122
9 IgM 0.102 0.000 0.235 0.164
10 IgM 0.125 0.000 0.171 0.118
5 IgG2a 0.204 0.000 0.137 0.094
11 IgM 0.133 0.000 0.115 0.136
12 IgG3 0.158 0.044 0.144 0.106
13 IgG3 0.213 0.000 0.139 0.119
15 IgG2a 0.228 0.000 0.021 0.022
16 IgG3 0.163 0.000 0.036 0.033
18 IgM 0.184 0.036 0.059 0.025
24 IgG2a 0.162 0.000 0.029 0.018
35 IgG3 0.167 0.000 0.021 0.017
36 IgM 0.174 0.000 0.027 0.029
32 IgG2a 0.246 0.128 0.024 0.025
FIG. 2. HPV-16 L1/L2 capsids purified through sucrose gradient sedimentation. (A) Electron microscopy. The bar represents 100 nm. (B) Proteins
were lysed by boiling in sample buffer, electrophoresed in 10% SDS–polyacrylamide gels, and stained by the silver stain method or (C) analyzed by
immunoblotting with the anti HPV-16 L1 and antisera to GST-L2. Molecular size standards are on the left.
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DISCUSSION
In this study we characterized mouse MAbs reactive
with intact L1/L2 capsids of HPV-16. Although the sera
from the immunized mice reacted with L1 capsids
strongly, 17 of a total of 18 MAbs were anti-L2. The
reason almost all of the hybridomas we obtained se-
creted anti-L2 MAbs is unclear at present. The similar
result that all of 12 MAbs obtained from Balb/c mice
immunized with intact virions of HPV-1 were anti-L2 has
been reported (Yaegashi et al., 1991). Since immunoge-
nicity is different from antigen to antigen, one of the
possible explanations is that we might have scarified
mice at the time the production of anti-L2 antibodies
was dominant. Eleven anti-L2 MAbs recognized linear
epitopes located in the N-terminal region of L2 protein
(aa 1–140). The 6 anti-L2 MAbs not reactive with any of
the linear L2 antigens may recognize either conforma-
tional L2 epitopes or possibly L2-dependent conforma-
tional L1 epitopes. Seven MAbs reacted with P-69/81 (a
synthetic peptide with an HPV-16 L2 sequence of aa
69–81), indicating that the region containing aa 69–81 is
a surface immunodeterminant of L2.
The HPV-16 L2 region of aa 62–81 has been located on
the surface of the L1/L2 capsids by Heino et al. (1995).
They examined reactivities of a series of guinea pig and
rabbit antisera raised by immunization with synthetic
peptides having HPV-16 L2 sequences. Antibodies
against peptides with aa 32–51, 62–81, 212–232, and
362–381 bind to intact L1/L2 capsids. The topographical
location of the region close to the N-terminus of L2
displayed on the surface of the L1/L2 capsids is consis-
tent with the case of BPV-1 virions (Wen et al., 1997).
Three anti-L2 MAbs recognizing epitopes in the region of
aa 61–123 of BPV-1 L2 can access and bind to their
epitopes on the intact virions. The topographical location
of L2 seems to be common to papillomavirus capsids.
The human serum sample positive for anti-HPV-16, -18,
-58, or -6b L1 capsids reacted with P-69/81. The data
indicate that the region of aa 69–81 of HPV-16 L2 is an
immunodeterminant for humans. It is likely that the re-
gions of HPV-18, -58, and -6b L2 proteins containing
amino acid sequences similar to aa 69–81 of HPV-16 L2
(aa 70–82 of HPV-18 L2, aa 72–84 of HPV-58 L2, and aa
68–80 of HPV-6b L2) (Fig. 4) are common immunodeter-
minants among HPVs. Besides type-common epitopes,
the type-specific immunodeterminant regions of HPV-33
L2 (aa 117–130) (Volpers et al., 1995) and HPV-1 L2 (aa
102–108) (Yaegashi et al., 1991) have been reported to be
detectable. The MAbs not binding to P-69/81 in this study
may contain those recognizing type-specific epitopes of
HPV-16 L2.
Although the function of L2 within the capsid has not
TABLE 2
Reactivities of MAbs with Synthetic Peptides
MAb
ELISA titer (A450)
P-63/75 P-69/81
17 0.084 0.108
2 0.000 0.078
4 0.000 0.126
6 0.017 0.077
7 0.012 0.047
9 0.037 0.103
10 0.008 0.112
5 0.004 0.004
11 0.020 0.026
12 0.000 0.010
13 0.000 0.000
FIG. 3. Antigens used for characterization of MAbs. His-L2s, MBP-L2, and GST-L2 were expressed as fusion proteins (fused with His tag, maltose
binding protein, or glutathione S-transferase, respectively). A (aa 1–12) and B (aa 56–81) indicate the regions of which amino acid sequences are
conserved among L2 proteins of different HPVs (see Fig. 4).
FIG. 4. Alignment of the HPV-16 L2 amino acid sequence of the
homologous regions of L2 proteins from different HPVs. Amino acids
identical to those of HPV-16 are shaded. Synthetic peptides (P-1/12,
P-56/68, P-63/75, and P-69/81) contain the amino acid sequences of
HPV-16 L2, indicated by bold lines.
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been fully elucidated (Roden et al., 1996; Day et al., 1998),
antibodies against the N-terminal region of L2 proteins
[aa 45–173 for BPV-1 (Roden et al., 1994a,b), aa 11–200
for BPV-4 (Chandrachud et al., 1995; Gaukroger et al.,
1996), and aa 131–151 for BPV-4 (Campo et al., 1997)]
have been demonstrated to contain neutralizing activi-
ties. The surface region of L2 may play a role in the step
of viral entry to cells. Analyses of neutralizing activities of
the MAbs described in this study are currently in
progress.
MATERIALS AND METHODS
Recombinant baculovirus expressing HPV-16 L1 and
L2 genes
DNA fragments containing HPV-16 L1 ORF (nucleo-
tides 5637 to 7154) and L2 ORF (4237 to 5658) (Seedorf et
al., 1985) were subcloned, by PCR-primed introduction of
appropriate restriction sites, from an HPV-16 DNA clone
with nucleotide substitution of G for C at nucleotides
6240 (Matsumoto et al., 1997). The L1 and L2 ORFs were
inserted into pFastBacDUAL donor plasmid (GIBCO BRL,
New York, NY) between NotI and XbaI sites (for expres-
sion from the polyhedrin promoter) and between SmaI
and BamHI sites (for expression from p10 promoter),
respectively. The structure of the recombinant plasmid
was confirmed by DNA sequencing analysis and intro-
duced into Escherichia coli DH10Bac competent cells
that contain Bacmid DNA with a mini-attTn7 target site
and the helper plasmid (GIBCO BRL). The resultant re-
combinant Bacmid DNA was purified and transfected
into Sf9 cells, which were grown in suspension culture at
27°C in SFM medium (GIBCO BRL) supplemented with
3% fetal calf serum (FCS). Recombinant baculovirus
clones were purified by plaque isolation as described
previously (Matsumoto et al., 1997).
Antisera to HPV-16 L1 and L2 proteins
A mouse monoclonal antibody against HPV-16 L1 was
a commercial product (PharMingen, San Diego, CA). For
production of antisera to L2, an internal part of HPV-16 L2
(aa 141 to 243) was bacterially expressed as a fusion
protein with glutathione S-transferase (GST-L2) and pu-
rified by affinity column chromatography using glutathi-
one–Sepharose 4B (Pharmacia Biotech, Uppsala, Swe-
den). Balb/c mice were immunized with a mixture of
purified GST-L2 (50 mg per mouse) and Freund’s com-
plete adjuvant (DIFCO Laboratories, Detroit, MI) followed
by three injections of the antigen (25 mg per mouse)
mixed with incomplete adjuvant (DIFCO Laboratories) at
intervals of 2 to 4 weeks. Sera were collected 7 days
after the final injection.
Preparation of HPV-16 L1 capsids and L1/L2 capsids
Purified HPV-16 L1 capsids were prepared as de-
scribed previously (Matsumoto et al., 1997). HPV-16
L1/L2 capsids were produced in Sf9 cells infected with
the recombinant baculovirus capable of expressing
HPV-16 L1 and L2. Approximately 1.5 3 109 Sf9 cells
were infected with the recombinant baculovirus at a
m.o.i. of 10 to 30 for 1.5 h at a room temperature and
incubated for 2–3 days at 27°C. The infected cells col-
lected by centrifugation were resuspended in 15 ml of
phosphate-buffered saline (PBS, pH 7.2), disrupted by
brief sonication, layered onto 15 ml of 40% (wt/vol) su-
crose in PBS, and centrifuged in a BECKMAN SW28 rotor
at 25,000 rpm for 2 h at 4°C. The pellets were resus-
pended by gentle sonication in 35 ml of 27% (wt/wt) CsCl
in PBS and centrifuged in a BECKMAN SW28 rotor at
27,500 rpm for 20 h at 20°C. The capsid band (at a
density of 1.28 g/ml) was collected and dialyzed exten-
sively against PBS.
FIG. 5. Reactivity of 72 human serum samples to P-1/12, P-69/81, and
P-56/68. (A) 20 samples negative for anti-HPV-6b, -16, -18, and -58 L1
capsid antibodies. (B) 22 samples positive for anti-HPV-16 L1-capsid
and negative for anti-HPV-6b, -18, and -58 L1 capsids. (C) 30 samples
negative for anti-HPV-16 L1 capsid and positive for any of the anti-HPV-
6b, -18, and -58 L1 capsids. The bars represent the means of ELISA
titers (A450) and the significance of differences between means is
indicated by P values (t test).
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Immunization of mice with HPV-16 L1/L2 capsids
Purified HPV-16 L1/L2 capsids (20 mg per mouse) were
mixed with complete Freund’s adjuvant and injected sub-
cutaneously into Balb/c mice. The antigen (15 mg per
mouse) mixed with incomplete Freund’s adjuvant and the
antigen (15 mg per mouse) alone were injected to mice
subcutaneously at 4 weeks after the first immuni-
zation and intraperitonially at 6 weeks, respectively. Five
days after the final injection, spleen cells of the immu-
nized mice were fused to myeloma cell line X63-Ag8.653
(grown in RPMI medium containing 10% FCS) using the
standard method (Galfre et al., 1977). Hybridomas were
selected with hypoxanthine–aminopterin–thymidine
(Dainippon Pharmaceutical Co., Osaka, Japan). Antibody
in culture medium of each hybridoma clone was
screened by ELISA using intact L1/L2 capsids as the
antigen.
Purification of antigens used for epitope mappings
Histidine-tagged truncated L2 proteins of HPV-16 (His-
L2/330 and His-L2/173 contained aa 1 to 330 and 1 to
173, respectively) were expressed in Sf9 cells by recom-
binant baculoviruses constructed with pFastBacHT
(GIBCO BRL). These proteins were purified from cell
lysates using an Ni21 column (GIBCO BRL) by the man-
ufacturer’s standard procedure. MBP-L2 [C-terminal re-
gion containing aa 318 to 473 was fused with maltose
binding protein (MBP)] was bacterially expressed and
purified by affinity column chromatography (NEB, Bev-
erly, MA). Purities of antigen preparations were verified
by SDS–polyacrylamide gel electrophoresis. P-1/12,
P-56/68, P-63/75, and P-69/81 were BSA-conjugated syn-
thetic peptides with the HPV-16 L2 amino acid se-
quences corresponding to aa 1 to 12, 56 to 68, 63 to 75,
and 69 to 81, respectively. Syntheses and conjugation
to BSA were performed by Sawady Technology (Tokyo,
Japan).
ELISA
The antigens [1 mg/well for L1/L2 capsids and L1
capsids in PBS (pH 7.2), 2 mg/well for His-L2/330, His-
L2/173, MBP-L2, and GST-L2 (pH 9.6), and 50 mg/well for
BSA-conjugated peptides in carbonate buffer (pH 9.6)]
were incubated in wells of an ELISA plate (Dynatech
Laboratories, Chantilly, VA) for 14 to 16 h at 4°C. Wells
were blocked with 0.2% gelatin in PBS for overnight at
4°C. After three washings with PBS containing 0.05%
NP-40 and 0.05% Tween 20, cell culture supernatants of
hybridomas or the samples to be tested (300 ml/well)
were added to wells and incubated for 1 h at room
temperature. Horseradish peroxidase-conjugated goat
anti-mouse immunoglobulin (DAKO Corp., Carpinteria,
CA) (1:2000 in 1% BSA in PBS) was used as a secondary
antibody. A mixture of 0.01% H2O2 and o-phenylenedi-
amine (2 mg/ml) in 0.1 M citrate buffer (pH 4.7) was
added to the wells and the absorbancy at 450 nm (A450)
was measured. Specific absorbancy was calculated by
subtracting the absorbancy of mock using wells covered
with gelatin and a part of fusion proteins (MBP and
glutathione S-transferase) or BSA conjugated with syn-
thetic peptides.
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